Eton Pharmaceuticals (ETON) Depreciation & Amortization (CF) (2018 - 2025)

Eton Pharmaceuticals has disclosed Depreciation & Amortization (CF) across 8 years of filings, most recently posting $1.0 million for Q4 2025.

• Depreciation & Amortization (CF) for Q4 2025 came in at $1.0 million, up 186.48% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.0 million (up 252.88% YoY), and the FY2025 annual result was $4.0 million, up 252.88% from the prior year.
• Depreciation & Amortization (CF) came in at $1.0 million for Q4 2025 at Eton Pharmaceuticals, up from $1.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.2 million in Q2 2022 to a low of $85000.0 in Q2 2021.
• The 5-year median for Depreciation & Amortization (CF) is $243000.0 (2022), against an average of $416350.0.
• Across the five-year window, Depreciation & Amortization (CF) soared 1277.65% in 2022 and slumped 85.31% in 2023, its largest moves.
• Eton Pharmaceuticals' Depreciation & Amortization (CF) stood at $137000.0 in 2021, then soared by 83.94% to $252000.0 in 2022, then advanced by 28.97% to $325000.0 in 2023, then advanced by 9.23% to $355000.0 in 2024, then soared by 186.48% to $1.0 million in 2025.
• The last three Depreciation & Amortization (CF) figures came in at $1.0 million (Q4 2025), $1.0 million (Q3 2025), and $1.0 million (Q2 2025), per Business Quant data.